Compare CHMI & ONCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHMI | ONCY |
|---|---|---|
| Founded | 2012 | 1998 |
| Country | United States | Canada |
| Employees | 14 | N/A |
| Industry | Real Estate Investment Trusts | Pharmaceuticals and Biotechnology |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.0M | 94.0M |
| IPO Year | N/A | 2002 |
| Metric | CHMI | ONCY |
|---|---|---|
| Price | $2.60 | $1.00 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | $3.00 | ★ $7.33 |
| AVG Volume (30 Days) | 188.8K | ★ 966.8K |
| Earning Date | 05-07-2026 | 05-13-2026 |
| Dividend Yield | ★ 15.50% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $61.13 | $2,505.00 |
| P/E Ratio | $139.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.17 | $0.33 |
| 52 Week High | $3.14 | $1.51 |
| Indicator | CHMI | ONCY |
|---|---|---|
| Relative Strength Index (RSI) | 45.29 | 49.21 |
| Support Level | $2.50 | $0.94 |
| Resistance Level | $2.76 | $1.13 |
| Average True Range (ATR) | 0.05 | 0.09 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 31.25 | 46.97 |
Cherry Hill Mortgage Investment Corp is a fully integrated, internally managed residential real estate finance company focused on acquiring, investing in and managing residential mortgage assets in the United States. It invests in residential mortgage assets to generate current yields and risk-adjusted total returns for its stockholders over the long term, through dividend distributions and secondarily through capital appreciation. The company's reportable segments include investments in Residential mortgage-backed securities (RMBS), Investments in Servicing Related Assets, and All Others. It generates maximum revenue from the RMBS segment in the form of Interest income earned for servicing mortgage loans.
Oncolytics Biotech Inc is a clinical-stage biopharmaceutical company. The company is focused on the discovery and development of pharmaceutical products for the treatment of cancers that have not been treated with therapeutics. It is developing pelareorep, an immunotherapeutic agent that improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The other projects in the company's pipeline include Bracelet-1 for the treatment of Breast Cancer, Goblet cohort-1, and Goblet cohort-5 for the treatment of Gastro-Intestinal Cancer among others.